Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.81 |
| ▸ | CASP2 | P42575 | 1/20 | 0.72 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.67 |
| ▸ | NAAA | Q02083 | 1/20 | 0.67 |
| ▸ | FAAH | O00519 | 3/20 | 0.60 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.55 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5436704 | 1.00 | MEN1 (0.81) | MEN1KMT2ACASP2EPHX1NAAA | |
| SCHEMBL10866304 | 1.00 | MEN1 (0.81) | MEN1KMT2ACASP2EPHX1NAAA | |
| SCHEMBL2944555 | 1.00 | MEN1 (0.81) | MEN1KMT2ACASP2EPHX1NAAA | |
| SCHEMBL8210316 | 1.00 | MEN1 (0.81) | MEN1KMT2ACASP2EPHX1NAAA | |
| SCHEMBL1901704 | 1.00 | MEN1 (0.81) | MEN1KMT2ACASP2EPHX1NAAA | |
| SCHEMBL10866272 | 1.00 | MEN1 (0.81) | MEN1KMT2ACASP2EPHX1NAAA | |
| SCHEMBL8197425 | 1.00 | MEN1 (0.81) | MEN1KMT2ACASP2EPHX1NAAA | |
| SCHEMBL4501660 | 1.00 | MEN1 (0.81) | MEN1KMT2ACASP2EPHX1NAAA | |
| SCHEMBL8209020 | 1.00 | MEN1 (0.81) | MEN1KMT2ACASP2EPHX1NAAA | |
| SCHEMBL626501 | 1.00 | MEN1 (0.81) | MEN1KMT2ACASP2EPHX1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010093615-A2 | COMPOUNDS, THEIR SYNTHESES, COMPOSITIONS, AND METHODS TO TREAT CANCER | TULANE UNIVERSITY (US) | 2010-08-19 | — | — | WO | claimed |
| US-20180207276-A1 | MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2018-07-26 | — | — | US | disclosed |
| US-20160287713-A1 | MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2016-10-06 | — | — | US | disclosed |
| US-20120136073-A1 | Amine-Containing Transfection Reagents and methods for making and using same | Life Technologies Corporation (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120136073-A1 | Amine-Containing Transfection Reagents and methods for making and using same | Life Technologies Corporation (US) | 2012-05-31 | — | — | US | disclosed |
| WO-2010093615-A2 | COMPOUNDS, THEIR SYNTHESES, COMPOSITIONS, AND METHODS TO TREAT CANCER | TULANE UNIVERSITY (US) | 2010-08-19 | — | — | WO | disclosed |
| US-6117562-A | A THERMAL IMAGE TRANSFER INK LAYER FORMED ON THE SUPPORT; INK LAYER COMPRISING A COLORING AGENT, A RESIN AND A PLASTICIZER FOR LOWERING THE MELT VISCOSITY OF RESIN | RICOH COMPANY, LTD. (JP) | 2000-09-12 | — | — | US | disclosed |
| US-5716477-A | CONSISTS OF A SUPPORT AND THERMAL IMAGE TRANSFER INK LAYER FORMED ON SAID SUPPORT CONSISTS OF A COLORING AGENT AND A PLASTICIZER FOR LOWERING MELT VISCOSITY OF THE RESIN, HIGH THERMOSENSITIVITY ON CLOTH, PLASTIC, OR PAPER RECEIVER | RICOH COMPANY, LTD. (JP) | 1998-02-10 | — | — | US | disclosed |
| US-4575734-A | LEVCO DYES | RICOH COMPANY, LTD. (JP) | 1986-03-11 | — | — | US | disclosed |
| US-4562448-A | Heat-sensitive transfer medium | RICOH CO., LTD. (JP) | 1985-12-31 | — | — | US | disclosed |
| US-4547788-A | SHEET HAVING LAYER CONTAINING LEVCO DYE; ACCEPTOR SHEET CONTAININGCOLORING AGENT; POROUS FILLER | RICOH COMPANY, LTD. (JP) | 1985-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136073-A1 | Amine-Containing Transfection Reagents and methods for making and using same | SNRPA, NUDT21, SOAT2 | MEN1 746/4885KMT2A 908/4885CASP2 1820/4885 |
| US-20180207276-A1 | MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF | HDGF, ELANE, CD47 | MEN1 1309/4885KMT2A 3490/4885CASP2 1460/4885 |
| US-20160287713-A1 | MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF | HDGF, TTPA, ELANE | MEN1 592/4885KMT2A 2981/4885CASP2 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.